Open Access. Powered by Scholars. Published by Universities.®

Chemical Actions and Uses Commons™

Open Access. Powered by Scholars. Published by Universities.®

Articles 1 - 2 of 2

Full-Text Articles in Chemical Actions and Uses

Tramadol For Treatment Of Neurogenic Cough: A Retrospective Case Series, Benjamin Joseph Rubinstein, Sheela Saidha, John Todd Sinacori Jan 2026

Tramadol For Treatment Of Neurogenic Cough: A Retrospective Case Series, Benjamin Joseph Rubinstein, Sheela Saidha, John Todd Sinacori

Department of Otolaryngology (ENT) Faculty Publications

Objectives

Explore the efficacy of tramadol for neurogenic cough and describe the longitudinal treatment experience.

Methods

A retrospective case series of adults with chronic cough who were treated with tramadol for neurogenic cough. A complete response was defined as no pathologic coughing, and a partial response was defined as 50% or greater reduction in severity or frequency.

Results

Sixty-nine patients were included. 38% of patients reported a complete response with an additional 33% reporting a partial response. The most common successful dosing regimen was 50 mg BID. Age, gender, and BMI did not impact treatment response. Patients with a history …


Real-World Dupilumab Treatment Reduced Healthcare Resource Utilization And Medication Use In Patients With Crswnp, Joseph K. Han, Stella E. Lee, Anju T. Peters, Zachary Soler, Nehal Kamal, Scott Nash, Mark Corbett, Amr Radwan, Joshua Levy Jan 2026

Real-World Dupilumab Treatment Reduced Healthcare Resource Utilization And Medication Use In Patients With Crswnp, Joseph K. Han, Stella E. Lee, Anju T. Peters, Zachary Soler, Nehal Kamal, Scott Nash, Mark Corbett, Amr Radwan, Joshua Levy

Department of Otolaryngology (ENT) Faculty Publications

Background: Evidence of dupilumab's real-world effectiveness in patients with chronic rhinosinusitis with nasal polyps (CRSwNP) in US clinical practice is limited.

Objective: To investigate healthcare resource utilization (HCRU) and medication use in patients with CRSwNP before and after dupilumab initiation in real-world US clinical practice.

Methods: This retrospective observational study included adults with CRSwNP who initiated dupilumab 300 mg every 2 weeks between June 2019 and June 2022. Data including claims and electronic health records were extracted from the OM1 Real-World Data Cloud and Reg-ENT Registry. Medication use, healthcare visits, sinus procedures, and imaging were assessed during the 12 months …